Market Cap 2.76B
Revenue (ttm) 190.41M
Net Income (ttm) 20.89M
EPS (ttm) N/A
PE Ratio 230.22
Forward PE 14.44
Profit Margin 10.97%
Debt to Equity Ratio 0.10
Volume 660,802
Avg Vol 3,837,446
Day's Range N/A - N/A
Shares Out 52.12M
Stochastic %K 78%
Beta -2.22
Analysts Hold
Price Target $53.00

Company Profile

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 213 8444
Fax: 650 213 8383
Website: soleno.life
Address:
100 Marine Parkway, Suite 400, Redwood City, United States
11thestate
11thestate May. 4 at 3:21 PM
$SLNO investors: there is a new securities class action filed against Soleno Therapeutics over hiding safety problems tied to DCCR, including fluid retention and other adverse-event risks seen in trials and after launch. If you held shares between March 26, 2025, and November 4, 2025, you can join the case and track recovery here https://11th.com/cases/solenotherapeutics-investor-suit Lead plaintiff deadline: May 5, 2026. Anyone else holding?
0 · Reply
PhishTourFunds
PhishTourFunds May. 1 at 3:00 AM
$SLNO Wyckoff and a reversal on the one year 👀
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 5:52 PM
$SLNO Current Stock Price: $52.77 Contracts to trade: $55.0 SLNO May 15 2026 Call Entry: $0.04 Exit: $0.07 ROI: 84% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bahamuttheking
Bahamuttheking Apr. 28 at 5:19 PM
$SLNO so idk whats the play do i take the $53 per share and what happens if i dont?
0 · Reply
Chrissixdd
Chrissixdd Apr. 25 at 2:50 PM
been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 21 at 5:24 PM
$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?
1 · Reply
anachartanalyst
anachartanalyst Apr. 17 at 2:02 PM
$SLNO https://anachart.com/wp-content/uploads/ana_temp/1776434501_soc-img.jpg
0 · Reply
theoptionsplug
theoptionsplug Apr. 17 at 4:42 AM
THINGS TO WATCH, FRIDAY, 4/17/26 👁️ $ALLY $BA $SLNO $SPY $QQQ
0 · Reply
InvestKaki
InvestKaki Apr. 12 at 12:00 AM
$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone
0 · Reply
Latest News on SLNO
Wells Fargo downgrades Soleno on pending acquisition

2026-04-17T10:31:18.000Z - 26 days ago

Wells Fargo downgrades Soleno on pending acquisition

NBIX


Soleno Therapeutics downgraded to Hold from Buy at Stifel

2026-04-07T09:27:01.000Z - 5 weeks ago

Soleno Therapeutics downgraded to Hold from Buy at Stifel


Soleno Therapeutics downgraded to Hold from Buy at TD Cowen

2026-04-07T09:21:01.000Z - 5 weeks ago

Soleno Therapeutics downgraded to Hold from Buy at TD Cowen


Soleno downgraded to Perform from Outperform at Oppenheimer

2026-04-06T20:30:46.000Z - 5 weeks ago

Soleno downgraded to Perform from Outperform at Oppenheimer


Soleno Therapeutics downgraded to Hold from Buy at Laidlaw

2026-04-06T16:25:09.000Z - 5 weeks ago

Soleno Therapeutics downgraded to Hold from Buy at Laidlaw


Neurocrine to Buy Soleno for $2.9 Billion

Apr 6, 2026, 7:34 AM EDT - 5 weeks ago

Neurocrine to Buy Soleno for $2.9 Billion

NBIX


Neurocrine to buy Soleno Therapeutics for $2.9 billion

Apr 6, 2026, 7:07 AM EDT - 5 weeks ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

NBIX


Soleno Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

Soleno Therapeutics Earnings Call Transcript: Q4 2025


Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Nov 12, 2025, 10:56 AM EST - 6 months ago

Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm


Soleno Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Soleno Therapeutics Earnings Call Transcript: Q3 2025


Soleno Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Soleno Therapeutics Earnings Call Transcript: Q2 2025


11thestate
11thestate May. 4 at 3:21 PM
$SLNO investors: there is a new securities class action filed against Soleno Therapeutics over hiding safety problems tied to DCCR, including fluid retention and other adverse-event risks seen in trials and after launch. If you held shares between March 26, 2025, and November 4, 2025, you can join the case and track recovery here https://11th.com/cases/solenotherapeutics-investor-suit Lead plaintiff deadline: May 5, 2026. Anyone else holding?
0 · Reply
PhishTourFunds
PhishTourFunds May. 1 at 3:00 AM
$SLNO Wyckoff and a reversal on the one year 👀
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 5:52 PM
$SLNO Current Stock Price: $52.77 Contracts to trade: $55.0 SLNO May 15 2026 Call Entry: $0.04 Exit: $0.07 ROI: 84% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bahamuttheking
Bahamuttheking Apr. 28 at 5:19 PM
$SLNO so idk whats the play do i take the $53 per share and what happens if i dont?
0 · Reply
Chrissixdd
Chrissixdd Apr. 25 at 2:50 PM
been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 21 at 5:24 PM
$SLNO filed its Form 14D9 with the SEC yesterday that included, among other things, the revenue forecast prepared by SLNO mgmt/BOD & provided to $NBIX. We find the discrepancy between SLNO analyst consensus & SLNO mgmt/BOD to be stunning. This highlights the enormous risk relying on analyst consensus when guesstimating potential M&A exit valuations. Attached are screenshots of SLNO analyst consensus per Seeking Alpha as of the morning the acquisition was announced (4/6/26) and SLNO's 14D9 filing from yesterday. The 2nd attachment provides the differences by year between SLNO analyst consensus & the revenue forecast provided by SLNO mgmt/BOD. Note 5-year analyst estimates were 32% higher than SLNO mgmt/BOD. 10-year revenues were 50% higher. The flip side is it appears the $2.444B enterprise value paid was priced @ 0.70X 5-year revenues & 0.28X 10-year revenues. FWIW it's our experience peer comm'l-stage M&A exits are priced at 0.90 to 1.05X 5-year & 0.30 to 0.40X 10-year $XBI $IBB $PFE ?
1 · Reply
anachartanalyst
anachartanalyst Apr. 17 at 2:02 PM
$SLNO https://anachart.com/wp-content/uploads/ana_temp/1776434501_soc-img.jpg
0 · Reply
theoptionsplug
theoptionsplug Apr. 17 at 4:42 AM
THINGS TO WATCH, FRIDAY, 4/17/26 👁️ $ALLY $BA $SLNO $SPY $QQQ
0 · Reply
InvestKaki
InvestKaki Apr. 12 at 12:00 AM
$SPX $NBIX $SLNO $INTC $XCORP https://www.investkaki.com/p/billion-dollar-milestone
0 · Reply
dennismccain
dennismccain Apr. 11 at 3:10 AM
$SLNO About five weeks ago I posted this comment (see below) about this biotech company because its stock that had recently showed up on my list of growth stocks at a reasonable price. I’ve never really been comfortable or successful investing in biotech stocks, so I passed on the idea. Unfortunately for me that was a bad idea. The company recently announced that it was being bought out by another company at a very nice premium. I bring this whole thing up because regardless of my personal biases, likes, and dislikes, that list continues to identify fast growing, yet undervalued, companies. In this case another company recognized that value that I ignored and bought out the entire company. If I had bought those shares my ROI would have been about 50% for holding the shares for just 5 weeks.
0 · Reply
Ooil
Ooil Apr. 8 at 9:01 PM
$IFRX Have a look at $SLNO that back in 2022 was a $1 ticket, 2023 at $5 and early 2024 close to $50. Soleno just bought out in a $2.9B deal. Soleno had an exceptional P3 in an orphan disease and was heavily shorted. And we all know that InflaRx late breaker presentation in PG shows everything but futility and also orphan. Whats the new p value in PG again? How many shares shorted?
1 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 8 at 5:51 AM
$SLNO see you at 75
0 · Reply
MikiTrader
MikiTrader Apr. 8 at 5:24 AM
$SLNO Yeah, I think people made a really good call. Not just me.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 8 at 1:13 AM
The 1st attachment shows the collective $NBIX & $SLNO analyst consensus revenue ests as of the morning the M&A exit was announced incl highest analyst est, consensus, lowest analyst est, consensus excl the highest analyst est, & consensus excl both the highest & lowest analyst est. At the bottom we simply add the 2 together for an idea of what NBIX analyst ests may, again may, look like post M&A. We then show a "what-if" NBIX was acquired for a peer 0.35X multiple on 10-year collective consensus just for fun. This may be absurd considering SLNO exited at a 0.15X 10-year multiple. The graph compares the collective NBIX/SLNO 10-year analyst consensus & an assumed gross margin @ 97% (NBIX actual FY25 gross margin = 97%, SLNO = 99%) v. the actual 10-year revenue & gross margin projection prepared by $SGEN when SGEN was acquired for an EV of $42B. SGEN provided a 12 year forecast (projecting peak sales in Year 10). Compare NBIX/SLNO 10 year gross margin (even if too high) to SGEN $XBI $IBB
1 · Reply
Stockanuck
Stockanuck Apr. 7 at 6:00 PM
$UNH $SLNO $IBRX $SRPT $LLY Among these big five calls, there was a call option trade with bullish sentiment. It expires in 17 day(s) on April 24, 2026. Parties traded 25 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $1800.0 per contract. There were 4001 open contracts at this strike prior to today, and today 3958 contract(s) were bought and sold. 9 Health Care Stocks With Whale Alerts In Today's Session https://www.benzinga.com/insights/options/26/04/51687681/9-health-care-stocks-with-whale-alerts-in-todays-session
0 · Reply
Annet_why_net
Annet_why_net Apr. 7 at 3:53 PM
$OSRH Oops, did I forget to mention the dual-track commercialization? By decoupling the Consumer Wellness launch from the Medical Grade certification, Woori IO can hit the market immediately via Samsung, generating cash flow while clinical trials run in parallel. We don’t have to sit around waiting for FDA approval to start making money. $TERN $SLNO $NVO
1 · Reply
anachartanalyst
anachartanalyst Apr. 7 at 2:02 PM
$SLNO https://anachart.com/wp-content/uploads/ana_temp/1775570484_soc-img.jpg
0 · Reply
Trader1141
Trader1141 Apr. 7 at 12:02 PM
$PSTV Floor after FDA news… lol you d@mn right im going to byy some lol $HCAI $DRUG $SILO $SLNO
0 · Reply
PickAlpha
PickAlpha Apr. 7 at 11:57 AM
PickAlpha Morning Report - Company News: 2026.04.07 News Analysis - 1/3: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53.00 per share in cash via tender offer, with no financing condition and a $95.25 mn termination fee. | View: The binding $53.00 all-cash tender with no financing condition is positive… $NBIX $SLNO $XBI $IBB
0 · Reply